Recombinant Human CD79B Protein, hFc-tagged, FITC conjugated

Cat.No. : CD79B-239HF
Product Overview : FITC conjugated recombinant human CD79B protein (Ala29-Asp159), fused to human IgG1 Fc tag at C-terminus, was expressed in human 293 cells (HEK293).
Availability July 20, 2024
Unit
Price
Qty
  • Specification
  • Gene Information
  • Related Products
  • Download
Description : B-cell antigen receptor complex-associated protein beta chain (CD79b) is also known as B-cell-specific glycoprotein B29, Ig-beta,Immunoglobulin-associated B29 protein, B29 and IGB, which is a single-pass type I membrane protein containing one Ig-like V-type (immunoglobulin-like) domain and one ITAM domain.CD79b is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR).CD79b can enhance phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. Defects in CD79b are the cause of agammaglobulinemia type 6 (AGM6) that is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development.
Source : HEK293
Species : Human
Tag : Fc
Form : Lyophilized
Molecular Mass : The protein has a calculated MW of 41.8 kDa. The protein migrates as 50-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Protein length : 131
Endotoxin : < 1.0 EU/ μg by the LAL method.
Purity : > 92 % as determined by SDS-PAGE
Characteristic : Disulfide-linked homodimer
Labeled with FITC via amines
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 535 nm
Storage : For long term storage, the product should be stored at lyophilized state at -20 centigrade or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20 to -70 centigrade for 12 months in lyophilized state;
-70 centigrade for 3 months under sterile conditions after reconstitution.
Storage Buffer : Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5, 10% trehalose.
Reconstitution : It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 μg/μL. Centrifuge the vial at 4 centigrade before opening to recover the entire contents.
Gene Name : CD79B
Official Symbol : CD79B
Synonyms : CD79B; CD79b molecule, immunoglobulin-associated beta; CD79B antigen (immunoglobulin associated beta) , IGB; B-cell antigen receptor complex-associated protein beta chain; B29; Ig-beta; B-cell-specific glycoprotein B29; immunoglobulin-associated B29 protein; CD79b antigen (immunoglobulin-associated beta); IGB; AGM6
Gene ID : 974
mRNA Refseq : NM_000626
Protein Refseq : NP_000617
MIM : 147245
UniProt ID : P40259

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Reviews
  • Q&As

Customer Reviews (3)

Write a review
Reviews
04/26/2023

    Renowned for its reliability and consistency, this protein offers researchers the confidence to achieve accurate and reproducible results in their studies.

    11/16/2021

      The CD79B protein comes highly recommended for its outstanding performance in ELISA assays.

      10/26/2018

        One notable advantage of the CD79B protein is the excellent technical support provided by its manufacturer.

        Q&As (5)

        Ask a question
        How does CD79B-targeted immunotherapy differ from traditional chemotherapy in treating B cell malignancies? 03/27/2021

        CD79B-targeted immunotherapy aims to specifically target B cells, potentially reducing side effects compared to non-specific chemotherapy.

        How does CD79B contribute to the development of personalized treatment strategies for B cell diseases? 01/12/2021

        Analyzing CD79B expression helps tailor treatment plans, allowing for more personalized and effective approaches.

        Can CD79B be used as a biomarker for minimal residual disease in B cell malignancies? 05/13/2018

        Yes, monitoring CD79B levels can aid in detecting minimal residual disease, providing insights into treatment response.

        Are there any challenges or limitations associated with relying on CD79B as a diagnostic marker? 03/02/2017

        Variability in CD79B expression among different B cell disorders may pose challenges in its use as a standalone diagnostic marker.

        Are there any clinical trials investigating the therapeutic potential of CD79B-targeted drugs? 01/22/2016

        Yes, several clinical trials are exploring the efficacy of CD79B-targeted drugs in various B cell disorders.

        Ask a Question for All CD79B Products

        Required fields are marked with *

        My Review for All CD79B Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /
        • Service lnquiry:

        Stay Updated on the Latest Bioscience Trends